# C_2010163EN.01001501.xml

| 23.6.2010 | EN | Official Journal of the European Union | C 163/15 |
| --- | --- | --- | --- |

23.6.2010

EN

Official Journal of the European Union

C 163/15

---

Prior notification of a concentration

(Case COMP/M.5865 — Teva/Ratiopharm)

(Text with EEA relevance)

2010/C 163/05

| 1. | On 14 June 2010, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Teva Pharmaceutical Industries Limited (‘Teva’, Israel) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertakings Merckle GmbH, CT Arzneimittel GmbH and AbZ-Pharma GmbH (collectively the ‘Merckle/Ratiopharm group’ or ‘Ratiopharm’, Germany) by way of purchase of shares. |
| --- | --- |

1.

On 14 June 2010, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Teva Pharmaceutical Industries Limited (‘Teva’, Israel) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertakings Merckle GmbH, CT Arzneimittel GmbH and AbZ-Pharma GmbH (collectively the ‘Merckle/Ratiopharm group’ or ‘Ratiopharm’, Germany) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | for Teva: the development, production and marketing of generic and proprietary pharmaceutical products as well as biopharmaceuticals and active pharmaceutical ingredients, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Teva: the development, production and marketing of generic and proprietary pharmaceutical products as well as biopharmaceuticals and active pharmaceutical ingredients,

| — | for Ratiopharm: the development, production and marketing of generic pharmaceutical products and biopharmaceuticals. |
| --- | --- |

—

for Ratiopharm: the development, production and marketing of generic pharmaceutical products and biopharmaceuticals.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.5865 — Teva/Ratiopharm, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.5865 — Teva/Ratiopharm, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

---